nullJPM24: Unveiling San Francisco’s Sizzling ADCs as Hottest Tickets!”
TLDR: According to a new report from J.P. Morgan, antibody-drug conjugates (ADCs) were the hottest ticket in the biopharma industry in 2023, driving a spike in licensing deal proceeds. Despite a decrease